|
|
A Novel Treatment of Vasomotor Symptoms in Prostate Cancer Patients
|
1R43CA195910-01A1
|
$226,310
|
$226,310
|
NGUYEN, VIEN
|
AGYPHARMA, LLC
|
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
3P20CA192976-02S1
|
$20,000
|
$9,400
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-03
|
$144,556
|
$67,941
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
|
Core Support for Cancer Center
|
3P30CA013330-44S1
|
$199,871
|
$7,995
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
3P30CA013330-44S2
|
$199,989
|
$8,000
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
3P30CA013330-44S3
|
$500,000
|
$20,000
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
5P30CA013330-44
|
$3,746,138
|
$149,846
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Optimization of Non-Ablative Focused Ultrasound Therapy for Tumor Immunity
|
5F30CA200411-03
|
$48,576
|
$48,576
|
SKALINA, KARIN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Contributions of sympathetic signals to prostate cancer progression.
|
1F30CA203446-01A1
|
$43,576
|
$43,576
|
ZAHALKA, ALI
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-04
|
$346,525
|
$69,305
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis
|
1R01CA201458-01A1
|
$382,013
|
$382,013
|
ZHU, LIANG
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
2016 AUA Urologic Oncology Research Symposium: ""Forging New Paths in Research to Advance Urologic Oncology
|
1U13CA206383-01
|
$10,000
|
$3,400
|
BEST, CAROLYN
|
AMERICAN UROLOGICAL ASSOCIATION
|
|
|
Novel Androgen Receptor Degraders to Treat Castration-Resistant Prostate Cancer
|
1R44CA203199-01
|
$648,400
|
$648,400
|
WINKLER, JAMES
|
ARVINAS, INC.
|
|
|
Functional Investigation of the Mitochondrial Pyruvate Carrier in Prostate Cancer
|
5F30CA196108-02
|
$41,438
|
$41,438
|
BADER, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
The Role of Mitochondrial Heterogeneity in Pyruvate Flux in Prostate Cancer Progression
|
1R21CA205257-01
|
$206,843
|
$206,843
|
MCGUIRE, SEAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S1
|
$118,016
|
$7,081
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S2
|
$170,897
|
$10,254
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S3
|
$118,875
|
$7,133
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S4
|
$499,947
|
$29,997
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S5
|
$134,220
|
$8,053
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-10
|
$3,253,119
|
$195,187
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
METABOLOMIC PROFILING AND BIOLOGIC BASIS OF RACIAL DISPARITY IN PROSTATE CANCER
|
4U01CA167234-05
|
$324,183
|
$324,183
|
SREEKUMAR, ARUN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Reprogramming of Prostate Stromal Cells by Prostate Inflammation
|
1R21CA196570-01A1
|
$222,296
|
$222,296
|
XIN, LI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
The Notch Signaling in Prostate Homeostasis and Carcinogenesis
|
5R01CA190378-02
|
$362,569
|
$362,569
|
XIN, LI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-33S1
|
$125,651
|
$6,283
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-33S2
|
$124,999
|
$6,250
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-33S3
|
$37,400
|
$1,870
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-33S4
|
$350,000
|
$17,500
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
4P30CA033572-33
|
$2,520,000
|
$126,000
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Androgen Signaling in prostate cancer progression and CRPC development
|
7R01CA070297-18
|
$305,616
|
$305,616
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
A New Mechanism for Castration Resistant Prostate Cancer
|
7R01CA166894-04
|
$368,984
|
$368,984
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cellular and Molecular Properties of PINs in Prostate Tumorigenesis
|
7R21CA190021-03
|
$221,787
|
$221,787
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Androgen Receptor Action in Castration Resistant Prostate Cancer
|
4P01CA163227-04
|
$2,045,071
|
$2,045,071
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
SOX9 Mediation of AR and ERG Driven Prostate Cancer
|
5R01CA168393-03
|
$361,050
|
$361,050
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Akt isoform-specific signaling in breast cancer metastasis
|
5R00CA157945-05
|
$241,629
|
$60,407
|
CHIN, YUET MING REBECCA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Role of Axl in docetaxel resistance in prostate cancer
|
5R21CA187843-02
|
$160,515
|
$160,515
|
LIBERMANN, TOWIA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Characterizing the signaling pathways that regulate Skp2 oncogenic function
|
1R01CA200573-01A1
|
$395,738
|
$395,738
|
WEI, WENYI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
RASL-Seq Expression Profiling of FFPE Tissues
|
5R33CA183688-02
|
$325,428
|
$325,428
|
YEAKLEY, JOANNE
|
BIOSPYDER TECHNOLOGIES, INC.
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S1
|
$1,595,651
|
$95,739
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S2
|
$550,000
|
$33,000
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S3
|
$750,000
|
$45,000
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-03
|
$9,068,022
|
$544,081
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Co-targeting oncogenic pathways in advanced prostate cancer
|
1R01CA198097-01A1
|
$381,212
|
$381,212
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Quantitative Image Informatics for Cancer Research (QIICR)
|
3U24CA180918-04S1
|
$257,375
|
$87,508
|
KIKINIS, RON
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Quantitative Image Informatics for Cancer Research (QIICR)
|
4U24CA180918-04
|
$668,889
|
$227,422
|
KIKINIS, RON
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Impact of aging on prostate cancer with TMPRSS2-ETS gene fusion
|
1UH2CA213392-01
|
$30,000
|
$30,000
|
LI, ZHE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Advancement and Validation of Prostate Diffusion and Spectroscopic MRI
|
4R01CA160902-05
|
$492,649
|
$492,649
|
MAIER, STEPHAN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
The VITamin D and OmegA-3 TriaL (VITAL)
|
5R01CA138962-08
|
$3,166,796
|
$1,045,043
|
MANSON, JOANN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Multi-Modality MRI/CT Markers for Improved Assessment of Prostate Cancer
|
5R44CA199905-02
|
$640,660
|
$640,660
|
BRIGHT, ANDREW
|
C4 IMAGING, LLC
|
|
|
Role of the AR-ErbB3-Nrdp1 axis in mediating prostate cancer health disparities
|
1R15CA202757-01
|
$421,195
|
$421,195
|
VINALL, RUTH
|
CALIFORNIA NORTHSTATE UNIVERSITY
|
|
Total relevant funding to Prostate for this search: $240,985,347
|
